Emerging Treatments for Corticobasal Syndrome

Overview

Despite decades of research, no disease-modifying therapy has been approved for corticobasal syndrome (CBS). However, the therapeutic pipeline has expanded significantly in recent years, with multiple agents targeting the underlying tau pathology, neuroinflammation, and neuronal dysfunction. This page provides an in-depth analysis of emerging treatments currently in development for CBS.

Tau-Targeting Therapies

Immunotherapies

Anti-Tau Antibodies

Overview

Despite decades of research, no disease-modifying therapy has been approved for corticobasal syndrome (CBS). However, the therapeutic pipeline has expanded significantly in recent years, with multiple agents targeting the underlying tau pathology, neuroinflammation, and neuronal dysfunction. This page provides an in-depth analysis of emerging treatments currently in development for CBS.

Tau-Targeting Therapies

Immunotherapies

Anti-Tau Antibodies

Bepranemab (UCB0107)

• Mechanism: Humanized monoclonal antibody targeting [tau protein](/proteins/tau)
• Phase: Phase II clinical trials
• Status: Currently recruiting CBS patients
• Target: Extracellular tau to prevent propagation
• ClinicalTrials.gov: NCT04658199
• Reference: [Boxer et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32268356/)

• Mechanism: Anti-tau antibody targeting aggregated tau
• Phase: Phase II completed
• Status: Completed but no longer in active development for CBS
• Results: Did not meet primary endpoints in PSP, limited data in CBS

• Mechanism: Tau-directed antibody
• Phase: Tested in CBS/PSP
• Status: Negative results in Phase II
• Reference: [Hoglinger et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35613929/)

Mechanism of Action

Tau immunotherapy aims to:

Challenges in CBS

• CBS patient heterogeneity (multiple underlying pathologies)
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration
• Need for biomarker-driven patient selection
• Optimal timing of intervention (pre-symptomatic vs. symptomatic)

Tau Aggregation Inhibitors

FNP-223 (Ferrer) — [See dedicated page](/therapeutics/fnp-223)

• Mechanism: OGA (O-GlcNAcase) inhibitor — increases tau O-GlcNAcylation competing with pathological phosphorylation
• Phase: PROSPER trial (NCT06355531)
• Status: Enrollment complete (n=220 PSP patients)
• Target: O-GlcNAcase enzyme, increases protective tau O-GlcNAcylation

• Mechanism: Inhibits tau aggregation
• Status: Limited data specific to CBS
• Reference: [Wischik et al., 2021](https://pubmed.ncbi.nlm.nih.gov/32894568/)
• Note: Historical compound with mixed results

Microtubule Stabilizers

TPI-287 (Abeotaxane)

• Mechanism: Microtubule stabilizer, protects neuronal architecture
• Phase: Phase I randomized clinical trial
• Status: Completed
• Publication: JAMA Neurology (2020), PMID:31710340
• Finding: Assessed safety, tolerability, and pharmacodynamics
• Significance: One of few Phase I trials specifically targeting CBS

Kinase Inhibitors

Lithium

• Mechanism: GSK3beta inhibitor
• Potential: May reduce tau phosphorylation
• Status: Not studied specifically in CBS
• Note: Known toxicity limits clinical application

• Mechanism: Non-competitive GSK3beta inhibitor
• Status: Studied in PSP (negative results)
• Relevance: Not studied specifically in CBS

Neuroprotective Approaches

Mitochondrial Modulators

AMX0035 (Relyvrio)

• Mechanism: Fixed-dose combination of sodium phenylbutyrate ([HDAC](/entities/hdac-enzymes) inhibitor) + tauroursodeoxycholic acid (mitochondrial protector)
• Target: Mitochondrial dysfunction, [autophagy](/entities/autophagy) impairment, ER stress
• Phase: Phase 2b/3 ORION trial (NCT06122662)
• Status: Tested in PSP, may include CBS patients
• Approval: FDA-approved for ALS
• Significance: First combination therapy in late-stage testing for 4R tauopathies
• Reference: Targeting key pathological pathways in CBS

• Dose: 300-2400mg daily
• Mechanism: Supports mitochondrial function
• Evidence: Generally well-tolerated
• Reference: [Niemann et al., 2020](https://pubmed.ncbi.nlm.nih.gov/30612346/)

NAD+ Replenishment

NADAPT Study (NCT06162013)

• Mechanism: NAD+ precursor supplementation
• Target: Cellular energy metabolism
• Phase: Phase 2 randomized double-blind trial
• Status: Recruiting atypical parkinsonism including CBS
• Rationale: Strong preclinical evidence for NAD+ depletion in CBS
• Significance: Novel disease-modifying approach targeting energy metabolism

Anti-Inflammatory Agents

[Microglia](/cell-types/microglia-neuroinflammation)-Modulating Approaches

• Target: Neuroinflammation, a key feature of CBS pathology
• Status: Preclinical and early clinical development
• Approach: Modulating microglial activation to reduce harmful inflammation

Cell-Based Therapies

Stem Cell Approaches

Neurologic Stem Cell Treatment Study (NCT02795052)

• Mechanism: Intravenous and intrathecal neural stem cell administration
• Phase: Phase 1
• Status: Recruiting for PSP and CBD
• Assessment: Adverse events and preliminary efficacy over 24 months
• Reference: [Pascual et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34001234/)
• Goal: Replace damaged [neurons](/entities/neurons) or provide neurotrophic support

Device-Based Therapies

Transcranial Direct Current Stimulation (tDCS)

NCT07291687

• Mechanism: Non-invasive brain stimulation modulating cortical excitability
• Phase: Device study
• Status: Recruiting
• Target: Motor function improvement
• Approach: Combined with motor training

Transcranial Magnetic Stimulation (TMS)

NCT04468932

• Mechanism: Non-invasive brain stimulation
• Phase: Phase 2
• Status: Recruiting (PSP, may inform CBS)
• Target: Motor and cognitive symptoms

Scrambler Therapy

NCT05653778

• Mechanism: Non-invasive neuromodulation using electrical signals
• Target: Neuropathic pain in CBS
• Phase: Pilot trial
• Significance: Addresses quality of life issue in CBS patients

Vibrotactile Cueing (CUE1)

NCT06174948

• Mechanism: Vibrotactile cueing device for gait freezing
• Status: Recruiting (PD and related disorders)
• Institution: Queen Mary University, London
• Potential: May benefit CBS patients with movement initiation difficulties

Repurposed Drugs

GLP-1 Agonists

Exenatide

• Mechanism: [GLP-1 receptor](/entities/glp1-receptor) agonist
• Phase: Phase 3
• Status: Recruiting (PD, may include CBS)
• Rationale: Neuroprotective properties demonstrated in preclinical models
• Reference: Currently in trials for [Parkinson's disease](/diseases/parkinsons-disease)

Metabolic Agents

Metformin

• Potential: Neuroprotective properties
• Evidence: Observational data suggesting reduced neurodegeneration risk
• Status: Not specifically studied in CBS

• Evidence: Mixed epidemiological evidence
• Status: No randomized trial data in CBS

Biomarker-Driven Trials

Importance of Patient Selection

Recent advances in CBS diagnosis and biomarker development are enabling more targeted clinical trials:

Biomarker Categories

| Biomarker Type | Utility | Examples |
|---------------|---------|----------|
| Tau PET | Path burden | [18F]ABBV-964i, [18F]ABBV-965i, [18F]PI-2620 |
| CSF | Neurodegeneration | NfL, p-tau, t-tau |
| Blood | Accessible markers | [p-tau217](/biomarkers/p-tau-217), NfL |
| Genetic | Patient stratification | GRN, MAPT, [C9orf72](/entities/c9orf72) |

Clinical Trial Design Considerations

Challenges Specific to CBS

Modern Trial Approaches

• Subtype stratification: Using biomarkers to select homogeneous populations
• Adaptive designs: More efficient trial structures
• Remote monitoring: Digital biomarkers for continuous assessment
• Multi-arm trials: Testing multiple agents simultaneously

See Also

• [CBS/PSP Clinical Trials Guide](/therapeutics/cbs-psp-clinical-trials-guide)
• [Corticobasal Syndrome Treatment](/therapeutics/corticobasal-syndrome-cbs-treatment)
• [CSF Biomarkers for CBS/PSP](/biomarkers/csf-biomarkers-cortico-basal-syndrome-progressive-supranuclear-palsy)
• [Plasma Biomarkers for CBS/PSP](/biomarkers/plasma-biomarkers-cortico-basal-syndrome-progressive-supranuclear-palsy)
• [Tau Pathology Mechanisms](/mechanisms/tau-pathology)
• [Mitochondrial Dysfunction in CBD](/mechanisms/mitochondrial-dysfunction-cortico-basal-degeneration)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC

Related Analyses:

• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;